Palomids

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NamePalomids
Drug Alias NameP-529P-52901RES-529SG-00529Palomid-529
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsSerine/threonine-protein kinase AKT1 inhibitorsmTOR Complex 2 inhibitors +[6] 
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2PI3-kinase class I +[6] 
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDiffusion Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPaloma Pharmaceuticals IncNational Eye Institute (Nei)
Active IndicationsN/A
Inactive IndicationsMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A